Demyelinating diseases articles from across Nature Portfolio

An antibody screen of two distinct multiple sclerosis cohorts reveals an autoantibody signature that is detectable years before symptom onset and linked to a common microbial motif.

Findings of phase III trials of the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis were recently presented at the ACTRIMS Forum.

New data recently reported at the ACTRIMS Forum add to growing evidence of an aetiological role for Epstein–Barr virus infection in multiple sclerosis.

Mitochondrial DNA has been identified as a potential biomarker of multiple sclerosis disease activity and treatment response.

Both caloric restriction and obesity affect autoimmune diseases. The activation of brainstem neurons in the ventrolateral medulla (VLM) with fasting suppresses experimental autoimmune diseases. Stimulation of VLM neurons alters T cell traffic by redistributing immune cells to bone marrow and reduces inflammatory cytokine production, thus providing therapy of experimental autoimmunity.

T cells that are specific for B cells infected with Epstein–Barr virus are enriched in the cerebrospinal fluid of people with early multiple sclerosis, according to new research.